F A Greco

Summary

Affiliation: Sarah Cannon Cancer Center
Country: USA

Publications

  1. ncbi request reprint Phase II trial of vinflunine in relapsed small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:874-8. 2010
  2. ncbi request reprint Emerging role of topotecan in first-line therapy of small-cell lung cancer
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Clin Lung Cancer 4:279-87. 2003
  3. doi request reprint Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay
    F Anthony Greco
    Sarah Cannon Research Institute and Cancer Center, Tennessee Oncology, PLLC, Suite 100, 250 25th Avenue North, Nashville, TN, 37203, USA
    Mol Diagn Ther 19:91-7. 2015
  4. doi request reprint Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management
    F Anthony Greco
    Sarah Cannon Cancer Center and Research Institute, Tennessee Oncology, PLLC, 250 25th Avenue North Suite 100, Nashville, TN, 37203, USA
    Curr Treat Options Oncol 14:634-42. 2013
  5. doi request reprint Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Natl Cancer Inst 105:782-90. 2013
  6. ncbi request reprint Cancer of unknown primary site: evolving understanding and management of patients
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 10:518-24. 2012
  7. doi request reprint Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes
    F A Greco
    Department of Internal Medicine, Section of Medical Oncology, Sarah Cannon Cancer Center and Research Institute, Nashville 37203, USA
    Ann Oncol 23:298-304. 2012
  8. ncbi request reprint Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial
    F Anthony Greco
    The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville 37203, USA
    Cancer 95:1279-85. 2002
  9. ncbi request reprint Topotecan as first-line therapy for small cell lung cancer
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Lung Cancer 41:S9-16. 2003
  10. ncbi request reprint Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Lung Cancer 8:483-7. 2007

Collaborators

Detail Information

Publications112 found, 100 shown here

  1. ncbi request reprint Phase II trial of vinflunine in relapsed small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:874-8. 2010
    ..Vinflunine is a new microtubule inhibitor with preclinical activity in small cell lung cancer (SCLC). In this phase II trial, we evaluated vinflunine in patients with relapse-sensitive and refractory SCLC...
  2. ncbi request reprint Emerging role of topotecan in first-line therapy of small-cell lung cancer
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Clin Lung Cancer 4:279-87. 2003
    ....
  3. doi request reprint Poorly differentiated neoplasms of unknown primary site: diagnostic usefulness of a molecular cancer classifier assay
    F Anthony Greco
    Sarah Cannon Research Institute and Cancer Center, Tennessee Oncology, PLLC, Suite 100, 250 25th Avenue North, Nashville, TN, 37203, USA
    Mol Diagn Ther 19:91-7. 2015
    ..Gene expression profiling and a molecular cancer classifier assay (MCCA) may provide a new method of diagnosis when standard pathologic evaluation and immunohistochemical (IHC) staining is unsuccessful...
  4. doi request reprint Molecular diagnosis of the tissue of origin in cancer of unknown primary site: useful in patient management
    F Anthony Greco
    Sarah Cannon Cancer Center and Research Institute, Tennessee Oncology, PLLC, 250 25th Avenue North Suite 100, Nashville, TN, 37203, USA
    Curr Treat Options Oncol 14:634-42. 2013
    ..The era of empiric therapy has ended in favor of site-specific therapy, based on the precise diagnosis of the tumor type present in each patient...
  5. doi request reprint Molecular profiling diagnosis in unknown primary cancer: accuracy and ability to complement standard pathology
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Natl Cancer Inst 105:782-90. 2013
    ..However, validation of the accuracy and clinical value of MTP has been difficult because the anatomic primary site in most patients is never identified...
  6. ncbi request reprint Cancer of unknown primary site: evolving understanding and management of patients
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Clin Adv Hematol Oncol 10:518-24. 2012
    ..Further delineation of the molecular aberrations in advanced solid tumors, regardless of the primary tumor site, signals a more precise and perhaps more effective therapy for each patient...
  7. doi request reprint Cancer of unknown primary: progress in the search for improved and rapid diagnosis leading toward superior patient outcomes
    F A Greco
    Department of Internal Medicine, Section of Medical Oncology, Sarah Cannon Cancer Center and Research Institute, Nashville 37203, USA
    Ann Oncol 23:298-304. 2012
    ..The longer-term objective is to understand the biology of highly metastatic disease, leading to the development of future global therapeutic programs. Current clinical studies, such as CUP-ONE, will address some of these issues...
  8. ncbi request reprint Prospective randomized study of four novel chemotherapy regimens in patients with advanced nonsmall cell lung carcinoma: a minnie pearl cancer research network trial
    F Anthony Greco
    The Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville 37203, USA
    Cancer 95:1279-85. 2002
    ..The authors compared the toxicity, response rate, and progression free survival of four chemotherapy regimens for patients with advanced (Stage IIIB and IV) nonsmall cell lung carcinoma...
  9. ncbi request reprint Topotecan as first-line therapy for small cell lung cancer
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Lung Cancer 41:S9-16. 2003
    ..Several ongoing phase III studies will help to clarify the role of topotecan in the first-line treatment of SCLC...
  10. ncbi request reprint Paclitaxel/Carboplatin/gemcitabine versus gemcitabine/vinorelbine in advanced non-small-cell lung cancer: a phase II/III study of the Minnie Pearl Cancer Research Network
    F Anthony Greco
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN, USA
    Clin Lung Cancer 8:483-7. 2007
    ....
  11. doi request reprint Phase 2 study of mapatumumab, a fully human agonistic monoclonal antibody which targets and activates the TRAIL receptor-1, in patients with advanced non-small cell lung cancer
    F Anthony Greco
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, United States
    Lung Cancer 61:82-90. 2008
    ..The receptor for mapatumumab, TRAIL-R1, is expressed on NSCLC cell lines. This pharmacologic profile suggests that mapatumumab may have therapeutic benefit in the treatment of NSCLC...
  12. ncbi request reprint Carcinoma of unknown primary site: sequential treatment with paclitaxel/carboplatin/etoposide and gemcitabine/irinotecan: a Minnie Pearl Cancer Research Network phase II trial
    F Anthony Greco
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, Tennessee 37203, USA
    Oncologist 9:644-52. 2004
    ....
  13. pmc Molecular profiling in unknown primary cancer: accuracy of tissue of origin prediction
    F Anthony Greco
    Tennessee Oncology, PLLC, Nashville, Tennessee, USA
    Oncologist 15:500-6. 2010
    ..This retrospective, multi-institutional study evaluated the accuracy of tissue-of-origin prediction by molecular profiling in patients with carcinoma of unknown primary site (CUP)...
  14. ncbi request reprint Paclitaxel/carboplatin/etoposide versus paclitaxel/topotecan for extensive-stage small cell lung cancer: a Minnie Pearl Cancer Research Network randomized, prospective phase II trial
    F Anthony Greco
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Oncologist 10:728-33. 2005
    ..gsk.com) with paclitaxel, carboplatin (Paraplatin; Bristol-Myers Squibb), and etoposide (Etopophos, VePesid; Bristol-Myers Squibb) in patients with previously untreated extensive-stage small cell lung cancer...
  15. doi request reprint Treatment for patients with unknown primary carcinoma and unfavorable prognostic factors
    F Anthony Greco
    Sarah Cannon Cancer Center, Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Semin Oncol 36:65-74. 2009
    ..Improvements in diagnostic pathology and molecular characterization of these carcinomas are likely to soon help select more appropriate and tailored therapies for many of these patients...
  16. ncbi request reprint Gemcitabine, carboplatin, and paclitaxel for patients with carcinoma of unknown primary site: a Minnie Pearl Cancer Research Network study
    F Anthony Greco
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Centennial Medical Center, Nashville, TN 37203, USA
    J Clin Oncol 20:1651-6. 2002
    ..To evaluate the efficacy and toxicity of the novel chemotherapy combination that includes gemcitabine, carboplatin, and paclitaxel in the treatment of patients with carcinoma of unknown primary site...
  17. ncbi request reprint Paclitaxel and carboplatin adjuvant therapy alone or with radiotherapy for resected nonsmall cell lung carcinoma: a feasibility study of the Minnie Pearl Cancer Research Network
    F A Greco
    The Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Cancer 92:2142-7. 2001
    ....
  18. doi request reprint Molecular classification of cancers of unknown primary site
    F Anthony Greco
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Mol Diagn Ther 13:367-73. 2009
    ..Several clinical studies are in progress or planned to test this concept...
  19. ncbi request reprint Carcinoma of unknown primary site
    F A Greco
    Sarah Cannon Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, TN 36203, USA
    Cancer 89:2655-60. 2000
    ....
  20. ncbi request reprint Taxane-based chemotherapy for patients with carcinoma of unknown primary site
    F A Greco
    Sarah Cannon Cancer Center, 250 25th Avenue, North, Suite 412, Nashville, Tennessee 37203-1632, USA
    Cancer J 7:203-12. 2001
    ..CONCLUSION: Taxane-based chemotherapy for patients with carcinoma of unknown primary site appears to be clinically beneficial and is associated with long-term survival for a minority of patients at 2-, 3-, and 4-year follow-up...
  21. ncbi request reprint Weekly docetaxel with either gemcitabine or vinorelbine as second-line treatment in patients with advanced nonsmall cell lung carcinoma: Phase II trials of the Minnie Pearl Cancer Research Network
    J D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Nashville, TN 37203, USA
    Cancer 92:2391-8. 2001
    ..The current study was conducted to evaluate the feasibility, toxicity, and efficacy of weekly docetaxel when paired with either gemcitabine or vinorelbine as the second-line treatment of patients with advanced nonsmall cell lung carcinoma...
  22. ncbi request reprint Preoperative therapy with concurrent paclitaxel/carboplatin/infusional 5-FU and radiation therapy in locoregional esophageal cancer: final results of a Minnie Pearl Cancer Research Network phase II trial
    Anthony A Meluch
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer J 9:251-60. 2003
    ..This phase II study was designed to determine the feasibility, toxicity, and therapeutic efficacy of a novel outpatient combined-modality preoperative regimen in patients with localized esophageal cancer...
  23. ncbi request reprint Weekly docetaxel as a single agent and in combination with gemcitabine in elderly and poor performance status patients with advanced non--small cell lung cancer
    J D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Semin Oncol 28:21-5. 2001
    ..One patient developed bilateral pulmonary infiltrates, possibly treatment-related, and died of respiratory failure. Further evaluation of weekly docetaxel-based combinations is indicated. Semin Oncol 28 (suppl 9):21-25...
  24. ncbi request reprint Irinotecan, carboplatin, and imatinib in untreated extensive-stage small-cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    J Thorac Oncol 2:854-61. 2007
    ..Imatinib targets KIT expression, providing rationale for studying its role in combination with chemotherapy in SCLC in a multicenter phase II trial...
  25. ncbi request reprint Advanced ovarian cancer: long-term results of treatment with intensive cisplatin-based chemotherapy of brief duration
    J D Hainsworth
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
    Ann Intern Med 108:165-70. 1988
    ..To determine the efficacy of a 6-month course of combination chemotherapy with hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) in the treatment of advanced ovarian carcinoma...
  26. ncbi request reprint Gemcitabine in the second-line therapy of patients with carcinoma of unknown primary site: a phase II trial of the Minnie Pearl Cancer Research Network
    J D Hainsworth
    Sarah Cannon Minnie Pearl Cancer Center, Centennial Medical Center, Nashville, Tennessee, USA
    Cancer Invest 19:335-9. 2001
    ..Because gemcitabine has activity against a variety of adenocarcinomas, further evaluation of this agent as part of first-line therapy for patients with carcinoma of unknown primary site is appropriate...
  27. ncbi request reprint Weekly docetaxel in the treatment of elderly patients with advanced breast cancer: a Minnie Pearl Cancer Research Network phase II trial
    J D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Clin Oncol 19:3500-5. 2001
    ..To evaluate the efficacy and toxicity of docetaxel administered weekly to elderly or poor-performance status patients with advanced breast cancer...
  28. ncbi request reprint Peritoneal carcinomatosis of unknown primary site in women. A distinctive subset of adenocarcinoma
    C M Strnad
    Vanderbilt University Medical Center, Nashville, Tennessee
    Ann Intern Med 111:213-7. 1989
    ..To define the clinical features and results of systemic treatment in women with adenocarcinoma of unknown primary site involving predominantly the peritoneal surfaces...
  29. ncbi request reprint Long-term follow-up of patients treated with paclitaxel/carboplatin-based chemotherapy for advanced non-small-cell lung cancer: sequential phase II trials of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    J Clin Oncol 20:2937-42. 2002
    ..To provide long-term follow-up on the survival of patients with advanced non-small-cell lung cancer treated with paclitaxel/carboplatin-based regimens in a multicenter, community-based setting...
  30. ncbi request reprint Paclitaxel-based three-drug combinations for the treatment of small cell lung cancer: a review of the Sarah Cannon Cancer Center experience
    J D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Semin Oncol 28:43-7. 2001
    ..Randomized trials will be necessary to definitively evaluate the efficacy of these regimens as compared with traditional platinum/etoposide combinations. Semin Oncol 28 (suppl 4):43-47...
  31. ncbi request reprint The role of hexamethylmelamine in the combination chemotherapy of advanced ovarian cancer: a comparison of hexamethylmelamine, cyclophosphamide, doxorubicin, and cisplatin (H-CAP) versus cyclophosphamide, doxorubicin, and cisplatin (CAP)
    J D Hainsworth
    Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
    Am J Clin Oncol 13:410-5. 1990
    ..Our findings suggest that the addition of HMM to CAP chemotherapy prolongs the median survival in patients with ovarian cancer and limited residual disease following cytoreductive surgery...
  32. ncbi request reprint Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie pearl cancer research network
    A A Meluch
    Sarah Cannon Cancer Center, Nashville, TN, USA
    J Clin Oncol 19:3018-24. 2001
    ..To evaluate the toxicity and efficacy of combination chemotherapy with paclitaxel and gemcitabine in patients with advanced transitional-cell carcinoma of the urothelial tract...
  33. ncbi request reprint Phase II trial of high-dose weekly topotecan in patients with relapsed small-cell lung cancer (SCLC)
    D Shipley
    Sarah Cannon Research Institute, Nashville, TN Florida Cancer Specialists, Ft Myers, FL
    J Clin Oncol 26:19073. 2008
    ..We hypothesized that a higher topotecan dose could improve the ORR without significantly increasing toxicity...
  34. doi request reprint A randomized phase II trial of oral topotecan versus docetaxel in the second-line treatment of non-small-cell lung cancer
    Suzanne Jones
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lung Cancer 9:154-9. 2008
    ..This randomized phase II trial evaluated the efficacy and toxicity of oral topotecan compared with intravenous docetaxel in the second-line treatment of patients with non-small-cell lung cancer (NSCLC)...
  35. ncbi request reprint Phase II trial of weekly docetaxel, vinorelbine, and trastuzumab in the first-line treatment of patients (pts) with HER2-positive metastatic breast cancer (MBC)
    N W Peacock
    Sarah Cannon Research Institute, Nashville, TN Consultants in Blood Disorders and Cancer, Louisville, KY
    J Clin Oncol 26:1032. 2008
    ..We investigated the feasibility and safety of a 3-drug combination of trastuzumab, docetaxel, and vinorelbine as first-line therapy in HER2+ MBC...
  36. ncbi request reprint Paclitaxel, carboplatin, and long-term continuous infusion of 5-fluorouracil in the treatment of advanced squamous and other selected carcinomas: results of a Phase II trial
    J D Hainsworth
    Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 412, Nashville, TN 37203, USA
    Cancer 92:642-9. 2001
    ....
  37. ncbi request reprint A phase I trial of weekly paclitaxel plus prolonged oral eniluracil/5-fluorouracil in patients with refractory malignancies
    Suzanne F Jones
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville 37203, USA
    Oncologist 7:444-50. 2002
    ..This phase I study was conducted to determine the dose-limiting toxicity (DLT), maximum-tolerated doses, and recommended phase II doses of the combination of weekly intravenous paclitaxel and oral eniluracil/5-fluorouracil (5-FU)...
  38. ncbi request reprint Induction paclitaxel, carboplatin, and infusional 5-FU followed by concurrent radiation therapy and weekly paclitaxel/carboplatin in the treatment of locally advanced head and neck cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Nashville, TN 37203, USA
    Cancer J 8:311-21. 2002
    ..The purpose of this study was to evaluate the feasibility, toxicity, and efficacy of a novel combined-modality treatment for patients with locally advanced squamous carcinoma of the head and neck...
  39. ncbi request reprint A phase I dose-escalation study of NK012
    H A Burris
    Sarah Cannon Research Institute, Nashville, TN Nippon Kayaku Co, Ltd, Tokyo, Japan
    J Clin Oncol 26:2538. 2008
    ..NK012 accumulates as nanoparticles in tumors where it gradually releases EHC by chemical hydrolysis under neutral conditions. Accumulation and sustained release of EHC could result in increased efficacy of the drug...
  40. ncbi request reprint Paclitaxel/carboplatin (PC) plus bevacizumab/erlotinib as first-line treatment for patients (pts) with carcinoma of unknown primary (CUP) site
    F A Greco
    Sarah Cannon Research Institute, Nashville, TN Oncology Hematology Care, Inc, Cincinnati, OH
    J Clin Oncol 26:4607. 2008
    ..In this multicenter, community-based phase II trial, we evaluated PC in combination with bevacizumab/erlotinib...
  41. ncbi request reprint Phase II trial of satraplatin (S) and paclitaxel (P) in first-line advanced non-small cell lung cancer (NSCLC) treatment: Final results
    D S Thompson
    Sarah Cannon Research Institute, Nashville, TN GPC Biotech, Princeton, NJ
    J Clin Oncol 26:19023. 2008
    ..In this multicenter phase II trial we evaluated S and P in pts with newly diagnosed advanced NSCLC...
  42. ncbi request reprint Vinflunine (VFL) as salvage chemotherapy in hormone-refractory prostate cancer (HRPC)
    A A Meluch
    Sarah Cannon Research Institute, Nashville, TN Associates in Oncology and Hematology, Chattanooga, TN Oncology Hematology Care, Crestview, KY
    J Clin Oncol 26:16059. 2008
    ..In this multicenter phase II trial, we evaluated VFL as salvage chemotherapy in HRPC...
  43. ncbi request reprint Phase II trial of gemcitabine, docetaxel, and cetuximab in advanced non-small-cell lung cancer (NSCLC)
    J R Rubinsak
    Florida Cancer Specialists, Ft Myers, FL Sarah Cannon Research Institute, Nashville, TN Tennessee Oncology, Nashville, TN Mercy Hospital, Portland, ME
    J Clin Oncol 26:19045. 2008
    ..Cetuximab targets this receptor and is a standard treatment in colon and head and neck cancers. In this multicenter trial we evaluated cetuximab in combination with a non-platinum regimen in first-line advanced NSCLC treatment...
  44. ncbi request reprint Phase I study of JM-216 (an oral platinum analogue) in combination with paclitaxel in patients with advanced malignancies
    Suzanne Jones
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville 37203, USA
    Invest New Drugs 20:55-61. 2002
    ..Higher doses of JM-216 are associated with more severe thrombocytopenia and delayed hematologic recovery resulting in subsequent dosing delays...
  45. doi request reprint A phase II trial of gemcitabine/carboplatin with or without trastuzumab in the first-line treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Breast Cancer 8:425-31. 2008
    ....
  46. doi request reprint Single agent vinflunine in the salvage treatment of patients with castration-resistant prostate cancer: a phase II trial of the Sarah Cannon research consortium
    John D Hainsworth
    Sarah Cannon Research Institute Nashville, Tennessee 37203, USA
    Cancer Invest 28:275-9. 2010
    ..Treatment was well tolerated, with myelosuppression as the only frequent toxicity. Vinflunine has a low level of activity in the treatment of refractory metastatic prostate cancer, and should not be further developed for this indication...
  47. doi request reprint A phase II feasibility trial of dose-dense docetaxel followed by doxorubicin/cyclophosphamide as adjuvant or neoadjuvant treatment for women with node-positive or high-risk node-negative breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Breast Cancer 8:242-8. 2008
    ..Because docetaxel might be more active than paclitaxel in the treatment of metastatic breast cancer, we explored the feasibility of substituting docetaxel for paclitaxel in dose-dense adjuvant therapy...
  48. doi request reprint Phase II trial of docetaxal plus imatinib mesylate in the treatment of patients with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:237-42. 2009
    ..In this phase II trial, we added imatinib, a PDGFR inhibitor, to docetaxel in the first-line treatment of women with metastatic breast cancer (MBC)...
  49. ncbi request reprint Evolving role of irinotecan in small-cell lung cancer
    David R Spigel
    The Sarah Cannon Cancer Center, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 1:482-5. 2003
    ..In addition, several of the newer biologic targeted agents are being tested in SCLC in combination with newer chemotherapy regimens. The results from these trials are eagerly awaited...
  50. ncbi request reprint Tracheoesophageal (TE) fistula development in a phase II trial of concurrent chemoradiation (CRT) and bevacizumab (B) in limited-stage small-cell lung cancer (LS-SCLC)
    D R Spigel
    Sarah Cannon Research Institute, Nashville, TN Tennessee Oncology, Nashville, TN Florida Cancer Specialists, Ft Myers, FL
    J Clin Oncol 26:7554. 2008
    ..In this multicenter phase II trial we evaluated concurrent CRT and B in LS-SCLC and identified a potential risk for TE fistula formation...
  51. ncbi request reprint Phase II trial of radiation therapy/temozolomide followed by temozolomide/sorafenib in the first-line treatment of glioblastoma multiforme (GBM)
    R E Lamar
    Tennessee Oncology, Nashville, TN Sarah Cannon Research Institute, Nashville, TN Florida Cancer Specialists, Ft Myers, FL South Texas Oncology and Hematology, San Antonio, TX
    J Clin Oncol 27:2018. 2009
    ..2018 Background: Anti-angiogenesis agents have recently shown activity in the treatment of patients (pts) with GBM. We added sorafenib, a multi-targeted TKI, to the standard first-line treatment of patients with GBM...
  52. ncbi request reprint Randomized phase III comparison of paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan, both followed by gefitinib, in patients (pts) with carcinoma of unknown primary site (CUP)
    J D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN Tennessee Oncology, Nashville, TN Oncology Hematology Care, Cincinnati, OH Grand Rapids Clinical Oncology Program, Grand Rapids, MI
    J Clin Oncol 27:4631. 2009
    ..Several regimens have been active in phase II trials, but no randomized comparison of newer regimens have been completed. In this multicenter randomized phase III trial, we compared the efficacy and toxicity of 2 active regimens...
  53. ncbi request reprint Unknown primary cancer (UPC): Accuracy of tissue of origin prediction by molecular profiling
    F A Greco
    Sarah Cannon Research Institute, Nashville, TN bioTheranostics, San Diego, CA
    J Clin Oncol 27:11070. 2009
    ..We then compared the RT-PCR diagnosis with the subsequent clinical diagnosis...
  54. ncbi request reprint A comparison of hexamethylmelamine (altretamine), cyclophosphamide, doxorubicin, and cisplatin (H-CAP) vs. cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced ovarian cancer
    F A Greco
    Department of Medicine, Vanderbilt University Medical Center, Nashville, TN
    Cancer Treat Rev 18:47-55. 1991
    ..045). Treatment-related toxicity was similar for the two regimens. These findings suggest that the addition of HMM to CAP chemotherapy prolongs the median survival for patients with limited residual disease advanced ovarian cancer...
  55. doi request reprint Paclitaxel/carboplatin plus bevacizumab/erlotinib in the first-line treatment of patients with carcinoma of unknown primary site
    John D Hainsworth
    Sarah Cannon Research Institute, 3322 West End Avenue, Suite 900, Nashville, Tennessee 37203, USA
    Oncologist 14:1189-97. 2009
    ..This phase II trial evaluated the efficacy and toxicity of the combination of paclitaxel, carboplatin, bevacizumab, and erlotinib in the first-line treatment of patients with carcinoma of unknown primary site (CUP)...
  56. doi request reprint Tracheoesophageal fistula formation in patients with lung cancer treated with chemoradiation and bevacizumab
    David R Spigel
    Sarah Cannon Research Institute, 250 25th Avenue North, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 28:43-8. 2010
    ..Strategies to safely incorporate novel antiangiogenic agents into combined-modality therapy in lung cancer are needed...
  57. doi request reprint Phase II trial of irinotecan, carboplatin, and bevacizumab in the treatment of patients with extensive-stage small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 4:1555-60. 2009
    ..Bevacizumab's role in the treatment of small cell lung cancer (SCLC) is unknown. A multicenter phase II trial with bevacizumab plus chemotherapy was conducted in patients with untreated extensive-stage SCLC...
  58. doi request reprint Rituximab plus short-duration chemotherapy followed by Yttrium-90 Ibritumomab tiuxetan as first-line treatment for patients with follicular non-Hodgkin lymphoma: a phase II trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Lymphoma Myeloma 9:223-8. 2009
    ..To evaluate the efficacy and safety of treatment with Yttrium-90 (90Y) ibritumomab tiuxetan following completion of short-course rituximab/chemotherapy in patients with previously untreated follicular non-Hodgkin lymphoma...
  59. doi request reprint What is the role of novel taxanes in non-small-cell lung cancer?
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lung Cancer 9:S116-21. 2008
    ..Many other novel taxanes are at earlier stages of development and appear promising as single agents and in combination regimens. Safer and more effective taxanes could replace paclitaxel and docetaxel as standard treatments in NSCLC...
  60. doi request reprint Phase I/II trial of preoperative oxaliplatin, docetaxel, and capecitabine with concurrent radiation therapy in localized carcinoma of the esophagus or gastroesophageal junction
    David R Spigel
    Sarah Cannon Research Institute, 3322 West End Ave, Suite 201, Nashville, TN 37203, USA
    J Clin Oncol 28:2213-9. 2010
    ..This multicenter community-based phase I/II trial examined a modern triplet regimen comprised of oxaliplatin, docetaxel, and capecitabine (ODC) combined with radiation therapy (RT)...
  61. doi request reprint Phase II study of biweekly pemetrexed and gemcitabine in patients with previously untreated advanced non-small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:841-5. 2010
    ..Pemetrexed and gemcitabine are safe and active non-small cell lung cancer (NSCLC) therapies when administered every 3 weeks. Biweekly scheduling was studied in this phase II trial...
  62. doi request reprint Phase II study of cetuximab, docetaxel, and gemcitabine in patients with previously untreated advanced non-small-cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lung Cancer 11:198-203. 2010
    ..This multicenter, community-based trial was designed to examine the role of cetuximab in combination with a nonplatinum regimen...
  63. doi request reprint Brief-duration rituximab/chemotherapy followed by maintenance rituximab in patients with diffuse large B-cell lymphoma who are poor candidates for R-CHOP chemotherapy: a phase II trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Lymphoma Myeloma Leuk 10:44-50. 2010
    ..In this phase II trial, we treated this group of patients with a novel regimen containing 3 courses of rituximab/chemotherapy followed by maintenance rituximab...
  64. doi request reprint Phase II study of capecitabine in combination with thalidomide in patients with metastatic breast cancer
    Howard A Burris
    Sarah Cannon Research Institute, 250 25th Avenue North, Nashville, TN 37203, USA
    Cancer Invest 28:408-12. 2010
    ..These results do not support further investigation of thalidomide for MBC. The role of angiogenesis inhibition in breast cancer treatment should continue to be defined using more efficacious and specific inhibitors...
  65. ncbi request reprint A phase II trial of carboplatin and weekly topotecan in the first-line treatment of patients with extensive stage small cell lung cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Thorac Oncol 5:862-6. 2010
    ..In this multicenter, community-based phase II trial, we evaluated carboplatin and weekly topotecan in the previously untreated patients with extensive stage SCLC...
  66. doi request reprint Paclitaxel/carboplatin/etoposide versus gemcitabine/irinotecan in the first-line treatment of patients with carcinoma of unknown primary site: a randomized, phase III Sarah Cannon Oncology Research Consortium Trial
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN, USA
    Cancer J 16:70-5. 2010
    ..To compare the results of empiric first-line therapy with paclitaxel/carboplatin/etoposide (PCE) versus gemcitabine/irinotecan, both followed by single-agent gefitinib, in patients with carcinoma of unknown primary site...
  67. ncbi request reprint Phase II trial of FOLFOX6, bevacizumab, and cetuximab in the first-line treatment of metastatic colorectal cancer
    David R Spigel
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Adv Hematol Oncol 8:480-5, 498. 2010
    ..To examine FOLFOX/bevacizumab/cetuximab in the first-line treatment of metastatic colorectal cancer (mCRC)...
  68. doi request reprint A phase II randomized crossover study of liposomal doxorubicin versus weekly docetaxel in the first-line treatment of women with metastatic breast cancer
    Denise A Yardley
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    Clin Breast Cancer 9:247-52. 2009
    ..We aim to compare the efficacy and toxicity of liposomal doxorubicin and weekly docetaxel as first-line treatments for patients with metastatic breast cancer (MBC)...
  69. doi request reprint Oxaliplatin and capecitabine in the treatment of patients with recurrent or refractory carcinoma of unknown primary site: a phase 2 trial of the Sarah Cannon Oncology Research Consortium
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 116:2448-54. 2010
    ..In the current study, the combination of oxaliplatin and capecitabine in patients with recurrent and refractory CUP was examined...
  70. doi request reprint Neoadjuvant chemotherapy/gefitinib followed by concurrent chemotherapy/radiation therapy/gefitinib for patients with locally advanced squamous carcinoma of the head and neck
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee, USA
    Cancer 115:2138-46. 2009
    ..The authors evaluated the feasibility, toxicity, and efficacy of gefitinib added to first-line combined-modality therapy for patients with locally advanced squamous carcinoma of the head and neck...
  71. ncbi request reprint Rituximab as first-line and maintenance therapy for patients with indolent non-hodgkin's lymphoma
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Nashville, TN, USA
    J Clin Oncol 20:4261-7. 2002
    ....
  72. ncbi request reprint A Phase I trial of protracted oral fixed-dose temozolomide
    Suzanne F Jones
    The Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 104:1985-91. 2005
    ..The current Phase I trial was conducted to determine the dose-limiting toxicity (DLT), maximum tolerated dose, and recommended Phase II dose of oral fixed-dose temozolomide when administered for 5 of every 7 days on a continuous basis...
  73. ncbi request reprint Combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site: a Minnie Pearl Cancer Research Network Phase II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, Tennessee 37203, USA
    Cancer 104:1992-7. 2005
    ..The current study was performed to evaluate the activity of combination chemotherapy with gemcitabine and irinotecan in patients with previously treated carcinoma of an unknown primary site...
  74. ncbi request reprint Maximizing therapeutic benefit of rituximab: maintenance therapy versus re-treatment at progression in patients with indolent non-Hodgkin's lymphoma--a randomized phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 23:1088-95. 2005
    ..To compare the benefit of maintenance rituximab therapy versus rituximab re-treatment at progression in patients with previously treated indolent non-Hodgkin's lymphoma...
  75. ncbi request reprint Chemotherapy in metastatic and locally advanced non-small cell lung cancer
    David R Spigel
    The Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Semin Surg Oncol 21:98-110. 2003
    ..Progress in treatment in the advanced setting has led to advances in the care of locally advanced disease. Combination chemoradiotherapy is a standard treatment for locally advanced disease, and studies with newer agents are in progress...
  76. ncbi request reprint A phase II trial of preoperative concurrent radiation therapy and weekly paclitaxel/carboplatin for patients with locally advanced non-small-cell lung cancer
    John D Hainsworth
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:33-42. 2004
    ..Postoperative complications associated with this preoperative combined-modality regimen were more frequent than expected with resection alone...
  77. ncbi request reprint Weekly combination chemotherapy with docetaxel and gemcitabine as first-line treatment for elderly patients and patients with poor performance status who have extensive-stage small cell lung carcinoma: a Minnie Pearl Cancer Research Network phase II trial
    John D Hainsworth
    The Sarah Cannon Cancer Center Tennessee Oncology, Nashville, Tennessee, USA
    Cancer 100:2437-41. 2004
    ....
  78. ncbi request reprint Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer
    Howard Burris
    The Sarah Cannon Cancer Center Tennessee Oncology, 250 25th Avenue N, Suite 110, Nashville, TN 37203, USA
    J Clin Oncol 22:1621-9. 2004
    ..To assess the feasibility and toxicity of weekly paclitaxel/carboplatin with or without trastuzumab following initial treatment with trastuzumab...
  79. ncbi request reprint Weekly paclitaxel, estramustine phosphate, and oral etoposide in the treatment of hormone-refractory prostate carcinoma: results of a Minnie Pearl Cancer Research Network phase II trial
    Anthony A Meluch
    Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer 98:2192-8. 2003
    ..The objective of the current study was to evaluate the efficacy and toxicity of weekly paclitaxel, oral etoposide, and estramustine phosphate in the treatment of patients with advanced, hormone-refractory prostate carcinoma...
  80. ncbi request reprint First-line treatment with brief-duration chemotherapy plus rituximab in elderly patients with intermediate-grade non-Hodgkin's lymphoma: phase II trial
    John D Hainsworth
    The Sarah Cannon Cancer Center and Tennessee Oncology, Nashville, 37203, USA
    Clin Lymphoma 4:36-42. 2003
    ..This regimen provides a treatment option for elderly patients who are not considered candidates for standard CHOP/rituximab chemotherapy...
  81. ncbi request reprint Phase I. Trial of irinotecan and temozolomide in patients with solid tumors
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:41-5. 2003
    ..The recommended phase II doses of irinotecan and temozolomide on treatment arms 1 and 3 remain to be determined as patient accrual is currently ongoing...
  82. ncbi request reprint Phase I. Trial of irinotecan plus carboplatin in two dose schedules
    Suzanne F Jones
    Sarah Cannon Cancer Center, Tennessee Oncology, PLLC Nashville, Tennessee, USA
    Oncology (Williston Park) 17:36-40. 2003
    ..With this amended regimen, the recommended phase II doses are irinotecan at 90 mg/m2 in combination with carboplatin at AUC 2.0 on days 1 and 8, with treatment cycles repeated every 21 days...
  83. ncbi request reprint Single-agent rituximab as first-line and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center and Tennessee Oncology, Professional Limited Liability Corporation, Nashville, TN 37203, USA
    J Clin Oncol 21:1746-51. 2003
    ....
  84. ncbi request reprint Paclitaxel and mitoxantrone in the treatment of metastatic breast cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Cancer Center, Centennial Medical Center, 250 25th Avenue, North, Suite 110, Nashville, TN 37203, USA
    Cancer Invest 20:863-71. 2002
    ..In this phase II trial, we evaluated the combination of paclitaxel and mitoxantrone in an attempt to maintain efficacy and improve tolerability of this regimen...
  85. ncbi request reprint Single-agent gefitinib in patients with untreated advanced non-small-cell lung cancer and poor performance status: a Minnie Pearl Cancer Research Network Phase II Trial
    David R Spigel
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Lung Cancer 7:127-32. 2005
    ..Patients with advanced non-small-cell lung cancer (NSCLC) and poor performance status (PS) are often excluded from trials. Gefitinib is a safe oral agent that may benefit these patients...
  86. ncbi request reprint Weekly docetaxel/estramustine phosphate in patients with increasing serum prostate- specific antigen levels after primary treatment for prostate cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN E mail
    Clin Genitourin Cancer 4:287-92. 2006
    ..This phase II study was performed as a preliminary evaluation of the feasibility and efficacy of weekly docetaxel/estramustine in patients with prostate cancer and increasing serum PSA levels...
  87. doi request reprint Neuroendocrine carcinoma of unknown primary site
    David R Spigel
    Sarah Cannon Research Institute, Tennessee Oncology, PLLC, Nashville, TN, USA
    Semin Oncol 36:52-9. 2009
    ..Tumor grade/differentiation currently is an important determinant of the management of these patients, and therapy in the future will be based on a more precise knowledge of the unique biology of these tumors...
  88. ncbi request reprint Therapy of adenocarcinoma of unknown primary: are we making progress?
    F Anthony Greco
    Sarah Cannon Cancer Center, Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    J Natl Compr Canc Netw 6:1061-7. 2008
    ....
  89. doi request reprint Weekly treatment with bortezomib for patients with recurrent or refractory multiple myeloma: a phase 2 trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 113:765-71. 2008
    ..The purpose of the current study was to evaluate the efficacy and toxicity of weekly bortezomib in the treatment of patients with recurrent/refractory multiple myeloma...
  90. ncbi request reprint Paclitaxel, carboplatin, and topotecan in the treatment of patients with small cell lung cancer: a phase II trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    The Sarah Cannon Cancer Center, Nashville, Tennessee 37203, USA
    Cancer 94:2426-33. 2002
    ....
  91. doi request reprint Combination therapy with fludarabine and rituximab followed by alemtuzumab in the first-line treatment of patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase 2 trial of the Minnie Pearl Cancer Research Network
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, Tennessee 37203, USA
    Cancer 112:1288-95. 2008
    ....
  92. ncbi request reprint A phase I/II study of exisulind in combination with docetaxel/carboplatin in patients with metastatic non-small-cell lung cancer
    Suzanne F Jones
    The Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN 37203, USA
    Clin Lung Cancer 6:361-6. 2005
    ....
  93. ncbi request reprint Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma: a Minnie Pearl Cancer Research Network Study
    John D Hainsworth
    Sarah Cannon Research Institute, Nashville, TN 37203, USA
    J Clin Oncol 24:3548-54. 2006
    ..To evaluate the efficacy of chemotherapy with paclitaxel, carboplatin, and etoposide in advanced adult poorly differentiated neuroendocrine carcinomas...
  94. ncbi request reprint Molecular tumor profiling (MTP) in cancer of unknown primary site (CUP): A complement to standard pathologic diagnosis
    D S Thompson
    Tennessee Oncology, Nashville, TN Sarah Cannon Research Institute, Nashville, TN Associated Pathologists, Brentwood, TN Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN
    J Clin Oncol 29:10560. 2011
    ..The ability of MTP to improve diagnosis over standard pathology is undefined. We evaluated MTP on biopsies to assess accuracy and diagnostic ability...
  95. ncbi request reprint Combined modality therapy with radiation therapy (RT), chemotherapy, bevacizumab, and erlotinib in the treatment of patients (pts) with locally advanced squamous carcinoma of the head and neck
    A A Meluch
    Sarah Cannon Research Institute, Nashville, TN Tennessee Oncology, Nashville, TN Florida Cancer Specialists, Ft Myers, FL Chattanooga Oncology and Hematology Associates, Chattanooga, TN
    J Clin Oncol 27:6012. 2009
    ..In this phase II trial, we added bevacizumab and erlotinib to an active combined modality regimen in the first-line treatment of pts with locally advanced head and neck cancer...
  96. ncbi request reprint Paclitaxel-based combination chemotherapy in advanced non-small cell lung cancer
    F A Greco
    The Sarah Cannon Cancer Center, 250 25th Av. North, Suite 412, Nashville, TN 37203, USA
    Lung Cancer 34:S53-6. 2001
    ..These results in patients with advanced disease have important implications for neoadjuvant and/or adjuvant approaches in patients with lower stages of disease, and several studies are ongoing...
  97. ncbi request reprint Sorafenib and everolimus (RAD001) in the treatment of patients with advanced clear cell renal carcinoma (RCC): A Sarah Cannon Research Institute phase I/II trial
    D M Waterhouse
    Oncology Hematology Care, Inc, Cincinnati, OH Tennessee Oncology, Nashville, TN Consultants in Blood Disorders and Cancer, Louisville, KY Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Sarah Cannon Research Institute, Nashville, TN
    J Clin Oncol 29:4629. 2011
    ..Combined use of these agents may improve efficacy. This phase I/II trial established the maximum tolerated dose (MTD) for these agents when used in combination, and then evaluated this combination in advanced RCC...
  98. ncbi request reprint Phase II study of NK012 in relapsed small cell lung cancer
    E Raefsky
    Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN The Sarah Cannon Cancer Center, Nashville, TN Sarah Cannon Research Institute, Nashville, TN Sarah Cannon Research Institute Florida Cancer Specialists, Fort Myers, FL Sarah Cannon Research Institute Virginia Cancer Institute, Richmond, VA Nippon Kayaku Co, Ltd, Tokyo, Japan
    J Clin Oncol 29:7079. 2011
    ..This phase II trial was designed to evaluate NK012 in pts with sensitive relapsed (SR) and refractory relapsed (RR) SCLC...
  99. ncbi request reprint A pharmacokinetic (PK) and safety study of sorafenib plus capecitabine in advanced solid tumors
    C E McKay
    Tennessee Oncology, Nashville, TN Sarah Cannon Research Institute, Nashville, TN Onyx Pharmaceuticals, Emeryville, CA Bayer Pharmaceuticals, Montville, NJ
    J Clin Oncol 27:e14548. 2009
    ..This study is designed to evaluate the PK and overall safety of S in combination with capecitabine (C)...
  100. ncbi request reprint Carcinoma of unknown primary site (CUP): Outcomes in patients with a colorectal molecular profile treated with site-specific chemotherapy
    F A Greco
    Sarah Cannon Research Institute Tennessee Oncology, Nashville, TN Associated Pathologists, Brentwood, TN Sarah Cannon Research Institute and Tennessee Oncology, Nashville, TN M D Anderson Cancer Center, Houston, TX Sarah Cannon Research Institute, Nashville, TN
    J Clin Oncol 29:3563. 2011
    ..Accurate identification of CUP patients (pts) with a colorectal site of origin would be expected to improve treatment results by directing the use of colorectal cancer regimens rather than empiric CUP regimens...
  101. doi request reprint Treatment of advanced renal cell carcinoma with the combination bevacizumab/erlotinib/imatinib: a phase I/II trial
    John D Hainsworth
    Sarah Cannon Research Institute and Tennessee Oncology, PLLC, Nashville, TN 37203, USA
    Clin Genitourin Cancer 5:427-32. 2007
    ....